 | Up a level |
Journal Article
Heidenreich, A., Carl, S., Feyerabend, S., Gleissner, J., Gruellich, C., Heinrich, B., Merseburger, A., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Go, J., Golsorkhi, T., Abida, W. and Scher, H. I. (2018). TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 75 - 76. BASEL: KARGER. ISSN 2296-5262
Merseburger, A., Carl, S., Feyerabend, S., Gleissner, J., Grimm, M. -O., Gruellich, C., Heidenreich, A., Heinrich, B., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Passler, L., Shetty, S., Golsorkhi, T., Ryan, C. and Chowdhury, S. (2018). TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 74 - 75. BASEL: KARGER. ISSN 2296-5262
Mulders, Peter F. A., Martinez-Pineiro, Luis, Heidenreich, Axel, Babjuk, Marko, Colombel, Marc, Colombo, Renzo, Radziszewski, Piotr, Korneyev, Igor 
ORCID: 0000-0001-7347-1901, Surcel, Cristian, Yakovlevi, Pavel, Witjes, J. Alfred, Caris, Christien, Schipper, Raymond, Witjes, Wim P. J., Villers, A., Malavaud, B., Rouboud, G., Grimm, M. O., Retz, M., Wagenlehner, F., Stenzl, A., Olbert, P., Niegisch, G., Hakenberg, O., Goebell, P., Wirth, M., Bolenz, C., Tubaro, A., Selli, C., Porena, M., Kerst, M., van Melick, H., Antoniewicz, A., Chlosta, P., Palou, J., Ponce Diaz-Reixa, J., Alonso Dorrego, J. M., Llorente, C., Fernandez-Gomez, J., Alvarez Maestro, M., Alvarez-Ossorio, J. L., Sanchez Chapado, M., Ribal, M., Guix, M., Bellmunt, J., Villacampa, F., Schraml, J., Zachoval, R., Sinescu, I, Stoica, L., Sakalo, V, Matveev, V, Alekseev, B., Komyakov, B. and Van den Steen, Peter
(2019).
Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial.
Eur. Urol. Focus, 5 (5).
S. 849 - 853.
AMSTERDAM:
ELSEVIER.
ISSN 2405-4569
Stenzl, A., Feyerabend, S., Syndikus, I., Sarosiek, T., Kuebler, H., Heidenreich, A., Cathomas, R., Gruellich, C., Loriot, Y., Perez Gracia, S. L., Gillessen, S., Klinkhardt, U., Schroeder, A., Schoenborn-Kellenberger, O., Reus, V., Koch, S. D., Hong, H. S., Seibel, T., Fizazi, K. and Gnad-Vogt, U. (2017). Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041